CRIS
Curis, Inc.
CRIS
Curis, Inc.
On Wednesday, Curis Inc. (NASDAQ:CRIS) announced updated positive clinical trial results for its investigational drug emavusertib, alongside expanded trial timeline guidance.
Curis, Inc. (CRIS) Discusses Positive Data From Emavusertib Combination Study in Primary CNS Lymphoma Transcript